Phase 3 study for people with Leukaemia

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Syndax Pharmaceuticals
Registry number NCT07211958
Started 25 November 2025 Today 16 October 2026 Estimated completion 1 June 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Clinical Trial Site Kingswood NSW Recruiting
Clinical Trial Site Kogarah NSW Recruiting
Clinical Trial Site Randwick NSW Recruiting
Clinical Trial Site South Brisbane QLD Recruiting
Clinical Trial Site Melbourne VIC Recruiting
Clinical Trial Site Nedlands WA Recruiting
Clinical Trial Site Perth WA Recruiting
Clinical Trial Site Gosford NSW Recruiting
Clinical Trial Site Wollongong NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 12 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 468

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Participants must have newly diagnosed and previously untreated AML and be candidates for intensive chemotherapy.

* Presence of an NPM1 mutation.

* Eastern Cooperative Oncology Group performance status ≤2 (≤1 if \>65 years old); Karnofsky or Lansky ≥40.

* Have a life expectancy of ≥3 months as judged by the Investigator.

* Negative serum pregnancy test.

* Adequate liver, kidney, and cardiac function.

Key Exclusion Criteria:

* Diagnosis of active acute promyelocytic leukemia.

* Active central nervous system disease.

* Fridericia's corrected QT interval (QTcF) \>450 milliseconds at screening, diagnosis or suspicion of Long QT syndrome or family history of Long QT syndrome.

* Any gastrointestinal (GI) issue of the upper GI tract likely to affect oral drug absorption or ingestion.

* Any concurrent malignancy requiring active therapy (except breast or prostate cancer stable on or responding to endocrine therapy).

* Inability to swallow oral medication.

* Pregnant or nursing females.

* Participant has known active or chronic hepatitis B or active hepatitis C (HCV) infection or human immunodeficiency virus (HIV)-positive with detectable viral load.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Dates on the record

Started 25 November 2025
Estimated completion 1 June 2029
Registry last updated 25 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 25 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.